Northern Trust Corp Has $31.76 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Northern Trust Corp grew its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,371,639 shares of the biopharmaceutical company's stock after buying an additional 187,652 shares during the quarter. Northern Trust Corp owned 1.13% of Amicus Therapeutics worth $31,761,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Amicus Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock worth $275,619,000 after purchasing an additional 458,143 shares during the period. Wellington Management Group LLP increased its stake in Amicus Therapeutics by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after buying an additional 4,497,950 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Amicus Therapeutics by 3.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company's stock worth $30,779,000 after buying an additional 107,348 shares in the last quarter. Norges Bank purchased a new stake in Amicus Therapeutics during the 4th quarter worth approximately $29,033,000. Finally, Rock Springs Capital Management LP increased its stake in Amicus Therapeutics by 107.9% during the 4th quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company's stock worth $24,487,000 after buying an additional 1,349,145 shares in the last quarter.

Amicus Therapeutics Stock Performance

FOLD traded up $0.31 during trading hours on Friday, hitting $6.26. The company's stock had a trading volume of 1,991,856 shares, compared to its average volume of 2,784,373. The company has a 50-day simple moving average of $7.42 and a 200 day simple moving average of $8.95. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $1.93 billion, a PE ratio of -34.69, a PEG ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $12.65.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on FOLD shares. Wells Fargo & Company cut their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. UBS Group raised their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group cut their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amicus Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.